the thalidomide society logo
dividing graphic
Home
About Us
> What is Thalidomide?
History of Thalidomide
Compensation
Support
Publications
News
Newsletter
Contact Us

     Tel / Fax: 
     01462 438 212
     email:

     info@thalsoc.demon.co.uk










What is thalidomide?

The drug thalidomide was marketed in the United Kingdom under the brand name Distaval from April 1958. It was also known as Asmaval, Distaval Forte, Tensival, Valgis, Valgraine (Source - TVAC 1999).

Distaval was commonly given to women in the first three months of their pregnancy to combat morning sickness or sleeplessness. It was thought at first that it was an entirely safe drug, but in 1961 the connection was made between thalidomide and a huge rise in the number of malformed babies being born.

Distaval was withdrawn from sale in the UK in December 1961.

Thalidomide impairments
The main impairments caused by thalidomide affected the limbs. The usual disturbance was bilateral - either both arms or both legs - or all four limbs. The most severe of these malformations is phocomelia. This is a condition where the long bones of some or all limbs are misshapen and where the hands and feet, which can be either substantially fully-formed, malformed or rudimentary, arise almost on the trunk.

Although the main category of foetal malformation was phocomelia, there were other impairments covering a wide spectrum of limb disabilities ranging from a substantial shortening of the limbs or virtual limblessness to less physically disabling conditions. Other malformations occurred affecting the cardiovascular system, the gastrointestinal tract, kidney and the special sense organs.

These disabilities cause difficulties with mobility and dexterity. Limited dexterity creates difficulties with manipulation, reach and the ability to become individually responsible for personal care.

The drug harmed the developing foetus only if taken in the first three months of pregnancy. Studies have shown that the exact timing of the thalidomide intake and the severity and type of resulting malformations follow the recognised sequence of organ development. Ministry of Health Report 112 states that the children could "suffer reduction deficiencies of the limbs, malformations of the eyes, ears and deafness, defects of the heart and kidneys and malformations of the alimentary system." There were very few instances of children with additional learning disabilities.

The late Professor Smithells, of the Department of Child Health and Paediatrics at Leeds University, has said, "There was a dramatic disappearance of this type of deformity within a year of the drugís withdrawal."

Worldwide impact
The total number of babies damaged by thalidomide throughout the world was thought to be about 10,000. However, the number of people now living with thalidomide impairment is considerably less than this because there was a high infant mortality rate.

This was particularly true in Germany where the drug was contained in a preparation called Contergan, which was sold over the counter in pharmacies. The use of Contergan resulted in the births of 6,000 grossly malformed children, of whom 2,000 have survived. Lack of limbs, and therefore of skin area, resulted in extreme sensitivity to high temperatures and some deaths. Severe internal injuries have caused others.


© The Thalidomide Society 2006
Tel: 01462 438 212   email: info@thalsoc.demon.co.uk